12-21-2010

Evotec AG announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The ...

more

09-03-2010

Following the successful fulfilment of various Closing conditions, the sellers of 99.3% of the shares in DeveloGen AG transferred their shares to Evotec AG. Evotec AG issues 6,750,014 new Evotec Shares from its authorized capital as part consideration for the transaction. Following the ...

more

02-25-2010

DeveloGen AG announced that it will receive US$ 500,000 from the Juvenile Diabetes Research Foundation, New York, USA (JDRF). The funds are dedicated to aide in the research of mechanisms for the protection of beta cells. In this two year project titled "Development of Novel Therapeutic ...

more

03-02-2009

DeveloGen AG reported positive results from a Phase 1 study for DG3173, a novel somatostatin analogue. The results of the study indicate that DG3173 has an excellent safety and tolerability profile at all doses administered. The Phase 1 trial was designed as a randomized, double-blind, ...

more

11-20-2003

Peptor Ltd., a biopharmaceutical company engaged in discovery and development of immunotherapeutic drugs to treat diabetes and other autoimmune diseases, and DeveloGen AG, a biology-driven drug discovery company developing novel therapies for diabetes and obesity, announced today that the ...

more

Study Provides Additional Support in Fight to Treat Diabetes

01-20-2003

DeveloGen AG announced the publication of important new diabetes data in the current early edition of Proceedings of the National Academy of Sciences. The study demonstrates the ability to normalize blood glucose levels in mice using insulin-secreting cells generated in a procedure driven by ...

more